Late-breaking one-year data show Abbott's next-generation Amulet 360 device continues to demonstrate high rates of left atrial appendage closure and low incidence of stroke
Abbott's TECTONIC clinical trial demonstrates strong 30-day outcomes and high procedural success for its investigational SonicForce Coronary Intravascular Lithotripsy System
Abbott initiates pivotal trial for Cephea device, an innovative treatment for mitral heart valve disease
Abbott launches whole-genome sequencing Oncodetect® molecular residual disease test to detect traces of cancer during and after treatment
Abbott presents new ESMO data showing 30-percent absolute improvement in sensitivity with the whole-genome sequencing Oncodetect® test in colorectal cancer
Abbott announces its intention to separate its global Nutrition business into an independent, publicly traded company
Abbott introduces Ensure® Max Protein 3-in-1 Muscle Support, bringing the benefits of a supplement stack into one scoop
Abbott launches SimpleScreen CRC blood test, joining Cologuard Plus® in its colorectal cancer screening portfolio
First Canadian Commercial Use of Abbott's Volt Pulsed Field Ablation System Advances Minimally Invasive Atrial Fibrillation Care
Abbott receives FDA approval for its TactiFlex Duo Ablation Catheter to treat people with abnormal heart rhythms
Abbott launches the first and only ready-to-feed liquid infant formula made with whole milk in the U.S. at similar price to its existing Similac powdered formula
Abbott's next-generation Amulet 360 device receives CE Mark to treat people with atrial fibrillation at risk of stroke
Abbott receives FDA authorization for world's first dual glucose-ketone sensing technology for people with diabetes
Abbott reaches agreements to resolve a portion of litigation involving its specialty formulas for preterm infants
Alvopetro Announces Q3 2026 Financial Results and an Operational Update Including 183-G2 Well Results
